• DRB as a Precision Tool for RNA Elongation Biology

  2026-08-14

  Explore how 5,6-Dichloro-1-β-D-ribofuranosylbenzimidazole (DRB) separates transcriptional supply from RNA stability and translation in ac4C-regulated stem-cell research. This guide connects CDK-dependent RNA polymerase II control with practical assay design, HIV transcription inhibition, and antiviral research.

• PTT and CD47 Blockade in Oral Cancer

  2026-08-14

  A 2026 study shows that photothermal therapy can overcome two major barriers to CD47-based macrophage therapy in oral squamous cell carcinoma: insufficient eat me signaling and poor immune-cell access. By inducing calreticulin exposure, releasing immunogenic danger signals, and remodeling the tumor extracellular matrix, photothermal therapy substantially improved macrophage phagocytosis and tumor control when combined with CD47 blockade.

• Cefepime in Resistance and CNS Models

  2026-08-13

  Cefepime (BMY-28142) offers translational researchers a mechanistically defined tool for linking bacterial cell-wall inhibition, carbapenemase-associated resistance, and central nervous system infection research. This perspective connects resistance surveillance with assay design, neurotoxicity studies, and reproducible bacterial infection models.

• Chlorpromazine Assay Reliability Guide

  2026-08-13

  Learn how Chlorpromazine, SKU C6410, can support more reproducible receptor, viability, proliferation, and cytotoxicity workflows. This scenario-based guide covers solvent compatibility, protocol controls, nanoparticle-study interpretation, and practical supplier selection using documented product specifications and relevant literature.

• A-1155463: Mechanism-First BCL-XL Translation

  2026-08-12

  A mechanism-first perspective on using the selective BCL-XL inhibitor A-1155463 to map apoptotic dependencies, validate resistance biology, and design translational cancer studies without overstating preclinical evidence.

• Cyclosporin A Workflows for Mechanistic Research

  2026-08-12

  Cyclosporin A enables mechanism-first studies of calcineurin-NFAT signaling, cyclophilin-linked mitochondrial injury, and immune suppression. This guide translates the compound’s handling requirements into practical workflows while using a recent bioavailability study to sharpen assay design without overstating cross-application evidence.

• Gasdermin C Reprograms PDAC Stemness and Immunity

  2026-08-11

  This study identifies Gasdermin C (GSDMC) as a transcriptionally active driver of pancreatic ductal adenocarcinoma stemness, metastasis, and immune evasion, independent of classical pyroptosis. Its findings connect ADAM17-dependent cleavage and nuclear localization of GSDMC to CXCL9-regulated immune suppression and suggest combination strategies with KRASG12D inhibition or PD-1 blockade.

• Click-Compatible BmTyr Proximity Labeling in T Cells

  2026-08-10

  The reference study develops a copper-dependent BmTyr proximity-labeling platform that uses an alkyne-phenol probe and azide-bearing tags, avoiding the background associated with endogenous biotinylation. In primary T cells, the approach supports fluorescence imaging, affinity enrichment, mass spectrometry, and antibody-independent chemiluminescent validation, while revealing a chromatin-associated localization of NKAP.

• Exosomes, TIE2-Expressing Macrophages, and Angiogenesis

  2026-08-09

  The reference study identifies a direct communication route in cervical cancer: exosomes released by TIE2-high tumor cells transfer TIE2 protein to macrophages and induce a proangiogenic TEM phenotype. By combining patient-tissue analysis, database correlation, cell experiments, and in vivo validation, the work links tumor-cell protein trafficking with angiogenesis and provides a mechanistic framework for studying the tumor microenvironment.

• SLC2A5 Fructose Metabolism in Primary CNS Lymphoma

  2026-08-08

  This Advanced Science study uses single-cell RNA and B-cell receptor profiling to define how glucose deprivation and hypoxia reshape metabolism and immune function in primary central nervous system lymphoma. It identifies SLC2A5-mediated fructose utilization in lymphoma cells and tumor-supportive macrophages as a potential metabolic vulnerability, supported by genetic and pharmacologic experiments.

• PCN-GR Control of Hippocampal CYP in Phenytoin Toxicity

  2026-08-07

  The reference study identifies a tissue-specific mechanism by which pregnenolone 16α-carbonitrile suppresses hippocampal cytochrome P450 expression and reduces phenytoin-associated neuronal injury. Its central innovation is the demonstration that this protection depends on glucocorticoid receptor signaling rather than the expected pregnane X receptor pathway, highlighting the importance of organ-specific nuclear receptor pharmacology.

• N3-kethoxal: Precision RNA Probing & Genomic Mapping in Acti

  2026-08-07

  N3-kethoxal empowers researchers to label unpaired guanines in RNA and single-stranded DNA with unprecedented selectivity, enabling rapid, high-resolution mapping of nucleic acid structure and interactions. Its azide functional group supports flexible click chemistry workflows, outperforming traditional probes for both in vitro and in vivo applications.

• Gasdermin C Drives Stemness and Immune Evasion in PDAC

  2026-08-06

  This study uncovers a non-pyroptotic role for Gasdermin C (GSDMC) in pancreatic ductal adenocarcinoma (PDAC), demonstrating how GSDMC promotes cancer cell stemness and immune evasion by nuclear regulation of key genes. Targeting GSDMC cleavage or nuclear translocation reprograms the tumor microenvironment and sensitizes PDAC to immunotherapeutic interventions, suggesting new avenues for overcoming drug resistance in this lethal cancer.

• Cardiogreen (Indocyanine Green): Deep-Dive into Vascular Dia

  2026-08-06

  Explore the advanced science of Cardiogreen (Indocyanine Green) in vascular diagnostics and its evolving role in immunotherapeutic synergy. Gain insights into protocol optimization and the molecular mechanisms driving its expanding clinical impact.

• Protease Inhibitor Cocktail (EDTA-Free): Enabling Plant Prot

  2026-08-05

  Explore how the Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO) advances plant cell protein stability and empowers in-depth signaling studies. This article uniquely connects protease inhibition to emerging molecular insights and assay optimization.

451 records 8/31 page Previous Next First page 上5页 678910 下5页 Last page